IMPORTANT MEDICAL DISCLAIMER

This document provides comprehensive, evidence-based medical information for educational and reference purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment and consider the unique circumstances of each patient when making healthcare decisions. Dosages, indications, and medical practices may vary by region and individual patient factors. Consult current local guidelines, pharmacists, and specialists as needed. In emergency situations, immediate medical attention is paramount.

---

Snake Envenomation

Overview

• Definition: Snake envenomation is the injection of venom into a victim by a snake bite, leading to local tissue damage, systemic toxic effects, or both. It is a complex medical emergency requiring prompt and appropriate management.
• Epidemiology: Snakebite envenoming is a neglected tropical disease with significant global morbidity and mortality.
  • Incidence: Estimated 5.4 million snake bites occur globally each year, resulting in 1.8 to 2.7 million cases of envenoming.
  • Mortality: Approximately 81,000 to 138,000 deaths annually.
  • Morbidity: About 400,000 cases of permanent physical and psychological disability, including amputation, contractures, blindness, and renal failure.
  • Geographic Distribution: Predominantly affects populations in tropical and subtropical regions, particularly in South Asia, Southeast Asia, Sub-Saharan Africa, and Latin America. Most victims are rural agricultural workers, children, and those with limited access to healthcare.
• Classification: Snake venoms are complex mixtures of proteins, peptides, enzymes, and non-protein components that can produce a wide range of toxic effects. The clinical manifestations of envenomation largely depend on the snake family and species.
  • Viperidae (Vipers): Characterized by hinged fangs, a triangular head, and heat-sensing pits. Venom is typically hemotoxic, cytotoxic, and myotoxic.
    • Examples: Vipers (e.g., Daboia russelii, Echis carinatus, Bitis arietans), Pit vipers (e.g., Crotalus spp., Bothrops spp., Trimeresurus spp.).
    • Effects: Local pain, swelling, blistering, tissue necrosis; systemic coagulopathy (spontaneous bleeding, non-clotting blood), hypotension, acute kidney injury (AKI), rhabdomyolysis, thrombocytopenia.
  • Elapidae (Cobras, Mambas, Kraits, Coral Snakes): Characterized by fixed, short fangs. Venom is primarily neurotoxic, but some (e.g., cobras) also have significant cytotoxic effects.
    • Examples: Naja spp. (Cobras), Dendroaspis spp. (Mambas), Bungarus spp. (Kraits), Micrurus spp. (Coral snakes).
    • Effects: Primarily neurotoxic (pre- or post-synaptic paralysis), leading to ptosis, ophthalmoplegia, dysphagia, respiratory failure. Cytotoxic effects (e.g., cobra venom) can cause severe local necrosis. Minimal or no local swelling initially, except for cytotoxic elapids.
  • Atractaspididae (Stiletto Snakes/Mole Vipers): Primarily African and Middle Eastern. Venom causes severe local necrosis and pain, sometimes systemic effects.
  • Colubridae (Rear-fanged snakes): Most are non-venomous or mildly venomous to humans. A few species (e.g., Dispholidus typus - Boomslang, Thelotornis kirtlandii - Twig snake) have potent hemotoxic venom, causing coagulopathy.

Pathophysiology

• Mechanism: Snake venoms are complex cocktails of enzymes (e.g., phospholipases A2, metalloproteinases, serine proteinases, L-amino acid oxidases), toxins (e.g., neurotoxins, cytotoxins, cardiotoxins), and other biologically active molecules.
  • Hemotoxins: Affect blood clotting pathways.
    • Procoagulant: Activate Factor X, prothrombin, or directly degrade fibrinogen (e.g., many Viperidae). This leads to consumption coagulopathy, resulting in a paradoxical bleeding state.
    • Anticoagulant: Inhibit clotting factors.
    • Platelet aggregation inhibitors/activators: Disrupt platelet function.
    • Hemorrhagins: Metalloproteinases that damage capillary endothelial cells, leading to bleeding.
  • Neurotoxins: Target the nervous system.
    • Presynaptic neurotoxins: (e.g., β-bungarotoxin, taipoxin) Damage nerve terminals, preventing acetylcholine release, leading to flaccid paralysis.
    • Postsynaptic neurotoxins: (e.g., α-bungarotoxin, α-cobratoxin) Block acetylcholine receptors at the neuromuscular junction, causing paralysis.
  • Cytotoxins/Myotoxins: Directly damage cells and tissues.
    • Phospholipase A2 (PLA2): Hydrolyze membrane phospholipids, causing cell lysis (e.g., myonecrosis, erythrocyte lysis).
    • Cardiotoxins: Directly damage cardiac muscle cells, causing arrhythmia or cardiac dysfunction (e.g., cobra cardiotoxins).
    • Hyaluronidase: Spreading factor that breaks down hyaluronic acid in connective tissue, facilitating venom dispersion.
• Risk Factors:
  • Geographic location: Residing or working in areas with high snake populations.
  • Occupation: Agricultural workers, farmers, plantation workers, herders, hunters.
  • Socioeconomic status: Poverty, limited access to healthcare facilities, reliance on traditional healers.
  • Behavioral: Walking barefoot or in open-toed footwear, sleeping on the ground, handling snakes, disturbing snake habitats (e.g., turning over rocks, collecting firewood).
  • Time of day/season: Increased risk during warmer months, and at dusk/night when many snakes are active.
  • Age: Children are at higher risk due to smaller body mass, making them more susceptible to systemic effects from a given venom dose.
• Protective Factors:
  • Education: Awareness of snake habitats, behaviors, and appropriate first aid.
  • Protective clothing: Wearing closed-toe shoes or boots, long trousers.
  • Environmental modification: Clearing vegetation around homes, using mosquito nets, sealing cracks in homes.
  • Lighting: Using flashlights when walking at night.
  • Avoidance: Not handling or approaching snakes, leaving them undisturbed.
  • Rapid access to healthcare: Availability of prompt and effective antivenom.

Clinical Presentation

Signs and Symptoms

The clinical picture varies significantly depending on the snake species, amount of venom injected, bite site, and victim's characteristics. A "dry bite" occurs when no venom is injected, accounting for ~20-50% of bites.

• Cardinal Features (Viperidae Envenomation):
  • Local: Immediate, severe, burning pain at the bite site. Rapidly progressive swelling (edema) that may extend up the limb. Ecchymosis, blistering, and hemorrhagic blebs. Lymphadenopathy (tender, enlarged regional lymph nodes).
  • Systemic:
    • Coagulopathy: Spontaneous bleeding (gingival bleeding, epistaxis, hematuria, hemoptysis, GI bleeding, intracranial hemorrhage). Blood that fails to clot (detected by 20-minute Whole Blood Clotting Test - 20WBCT).
    • Hypotension/Shock: Due to vasodilation, fluid extravasation, blood loss.
    • Acute Kidney Injury (AKI): Direct nephrotoxicity, hypotension, rhabdomyolysis.
    • Rhabdomyolysis: Muscle pain, weakness, dark urine (myoglobinuria).
    • Thrombocytopenia: Platelet consumption.
• Cardinal Features (Elapidae Envenomation):
  • Local: Often minimal local signs (mild pain, small fang marks, slight swelling), except for cobras which can cause severe local pain, swelling, blistering, and necrosis similar to viper bites.
  • Systemic (Neurotoxicity):
    • Early/Mild: Ptosis (drooping eyelids), diplopia (double vision), blurred vision, dysphagia (difficulty swallowing), dysarthria (slurred speech), facial muscle weakness.
    • Progressive/Severe: Progressive flaccid paralysis affecting neck muscles, then limbs, followed by respiratory muscles (diaphragm), leading to respiratory failure and arrest. Patients may appear alert but are unable to move or speak.
    • Autonomic features: Salivation, sweating, abdominal pain.
• Early Signs:
  • Local: Puncture marks (fang marks, typically 1 or 2, but can be multiple scratches), pain, localized swelling, redness.
  • Systemic: Nausea, vomiting, dizziness, lightheadedness, weakness, anxiety.
• Advanced Signs:
  • Local: Significant limb swelling, tight skin, tense compartments (suggesting compartment syndrome), tissue necrosis, large blisters, bullae.
  • Systemic: Severe bleeding, oliguria/anuria (renal failure), severe hypotension, respiratory distress/failure, altered mental status, convulsions.
• Atypical Presentations:
  • Dry Bites: No venom injected; patient presents with fang marks but no signs of envenomation. Requires observation for at least 8-12 hours.
  • Delayed Effects: Rare, but neurotoxic symptoms can be delayed for several hours after a bite, especially with Kraits. Coagulopathy may also take hours to manifest.
  • Minimal Local Signs with Severe Systemic Envenomation: Common with pure neurotoxic elapids (e.g., Kraits, Mambas).
  • Massive Envenomation: Rapid onset of severe systemic toxicity, overwhelming multiple organ systems.
  • Psychogenic Reactions: Vasovagal syncope, hyperventilation, panic attacks, not true envenomation.

Physical Examination

A thorough and repeated physical examination is crucial for assessing envenomation severity and monitoring progression.

• Inspection:
  • Bite Site: Identify fang marks (presence/absence, number, depth, spacing – though not reliable for species ID). Note color changes (redness, cyanosis, ecchymosis), swelling, blistering, hemorrhagic blebs, skin tension, signs of necrosis.
  • Regional: Examine regional lymph nodes for tenderness and enlargement.
  • Systemic: Observe for signs of bleeding (gingival, epistaxis, conjunctival hemorrhage, petechiae, purpura), respiratory distress (tachypnea, accessory muscle use, paradoxical breathing), altered mental status, ptosis, ophthalmoplegia, facial droop, general weakness.
  • Urine color: Dark urine (tea-colored) suggests rhabdomyolysis (myoglobinuria) or hemolysis.
• Palpation:
  • Bite Site: Assess warmth, tenderness, and firmness of the swelling. Mark the leading edge of the swelling with a pen and measure limb circumference at regular intervals (e.g., hourly).
  • Compartments: Palpate muscles for tenseness; significant firmness may suggest compartment syndrome (often associated with pain on passive stretch).
  • Pulses: Check peripheral pulses distal to the bite site; diminished or absent pulses may indicate significant swelling or arterial compression.
• Special Tests (Bedside):
  • 20-minute Whole Blood Clotting Test (20WBCT): This is a critical bedside test for detecting venom-induced consumption coagulopathy (VICC) in viper envenomation.
    • Procedure: Draw 2-5 mL of fresh venous blood (not arterial blood), place in a clean, dry, glass test tube (e.g., 10x75 mm) and leave undisturbed at ambient temperature. Observe after 20 minutes.
    • Interpretation: If the blood is still liquid (unclotted) after 20 minutes, it indicates significant coagulopathy and suggests systemic envenomation requiring antivenom. If it clots firmly, coagulopathy is likely absent (though a strong clot does not rule out mild envenomation or future progression). Repeat every 6-12 hours until stable if initial test is negative.
  • Limb Circumference Measurement: Use a measuring tape to document the circumference of the affected limb at fixed landmarks (e.g., 5 cm proximal and distal to the bite site, or at fixed distances from elbow/knee) at regular intervals (e.g., every 15-30 minutes initially, then hourly) to monitor swelling progression.

Diagnostic Approach

Diagnosis is primarily clinical, based on history, physical examination, and bedside clotting tests. Identifying the snake is helpful but often not possible or reliable.

History Taking

• Key Questions:
  • Time of bite: Crucial for assessing symptom progression and guiding antivenom timing.
  • Circumstances of bite: Where and how it occurred (e.g., walking, sleeping, disturbing a snake) – helps assess risk and potential species.
  • Snake description: If seen, ask about color, pattern, size, head shape. Caution: Do not rely solely on patient description for species identification, as misidentification is common and dangerous.
  • Immediate symptoms: Local pain, swelling, dizziness, nausea, bleeding.
  • First aid measures: What was done immediately after the bite (e.g., tourniquet, incision, suction, traditional remedies) – these are often harmful.
  • Past medical history: Allergies (especially to horse/sheep serum, prior antivenom exposure), comorbidities (e.g., cardiac, renal disease, bleeding disorders).
  • Vaccination status: Tetanus prophylaxis.
• Red Flags:
  • Rapidly progressing local swelling (>1 cm/hour spread, or involving a joint within first 2-3 hours).
  • Evidence of systemic bleeding (gingival bleeding, epistaxis, hematuria, unprovoked bruising).
  • Presence of neurotoxic symptoms (ptosis, ophthalmoplegia, dysphagia, respiratory difficulty).
  • Hypotension or signs of shock.
  • Unclotted blood on 20WBCT.
  • Increasing pain on passive stretch, tense limb compartments.
  • Oliguria or anuria.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): Hemoglobin, hematocrit (to assess for blood loss/hemoconcentration), platelet count (thrombocytopenia common in viper envenomation).
  • Coagulation Profile: Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), International Normalized Ratio (INR), Fibrinogen levels. Elevated PT/aPTT and low fibrinogen indicate venom-induced consumption coagulopathy (VICC).
  • 20-minute Whole Blood Clotting Test (20WBCT): As described above, crucial bedside test.
  • Renal Function Tests: Serum creatinine, blood urea nitrogen (BUN) (to assess for AKI).
  • Electrolytes: Sodium, potassium, chloride, bicarbonate.
  • Creatine Kinase (CK): To detect rhabdomyolysis (elevated CK levels).
• Confirmatory:
  • Venom Detection Kits: While available in some research settings, generally not rapid or widely accessible enough for routine clinical decision-making in acute envenomation. Clinical syndrome and laboratory findings remain paramount.
• Monitoring:
  • Repeat CBC, coagulation profile (PT/aPTT, fibrinogen), 20WBCT, renal function, and CK levels every 6-12 hours after antivenom, and daily until resolution or stability.
  • Monitor urine output and color.

Imaging

• Recommended:
  • Plain X-ray of the bitten limb: To rule out retained fangs, foreign bodies, or associated bone fractures. May show soft tissue swelling.
  • Ultrasound: Can assess for fluid collections, abscess formation, or compartment integrity in cases of severe swelling. May help differentiate cellulitis from tissue necrosis.
• Advanced:
  • MRI: Can provide detailed assessment of soft tissue damage, muscle necrosis, and differentiate fluid accumulation from viable tissue. Less commonly used in acute settings due to time and cost, but may be useful in assessing late complications or guiding debridement.

Management

Management of snake envenomation is a medical emergency focused on immediate life support, prevention of venom absorption, specific antidote administration (antivenom), and supportive care.

Acute Management

• Immediate (Pre-hospital and ED arrival):
  1. Safety First: Ensure safety of patient and rescuers; identify but do not approach the snake.
  2. Reassurance: Keep the patient calm to reduce venom spread from increased blood flow.
  3. Immobilization: Keep the bitten limb still and at a comfortable, neutral position (not elevated or dependent). Use a splint or sling if available.
  4. Remove Constricting Items: Remove rings, bracelets, watches, and tight clothing from the bitten limb BEFORE swelling begins.
  5. Mark Swelling Progression: Mark the leading edge of local swelling with a pen every 15-30 minutes and measure limb circumference at fixed points.
  6. DO NOT:
     • Apply a tourniquet (arterial or venous).
     • Incise or suck the wound.
     • Apply ice or heat.
     • Use traditional remedies or herbal medications.
     • Administer electric shock.
  7. Rapid Transport: Transport the patient immediately to the nearest appropriate medical facility with antivenom.
• Stabilization (Emergency Department):
  1. Airway, Breathing, Circulation (ABCs): Assess and stabilize.
     • Airway: Assess for upper airway obstruction due to swelling (cobra bites to head/neck) or neurotoxic paralysis (tongue fall). Be prepared for intubation.
     • Breathing: Monitor respiratory rate, effort, oxygen saturation. Neurotoxic envenomation can cause progressive respiratory paralysis requiring mechanical ventilation.
     • Circulation: Establish at least two large-bore IV lines (18-gauge or larger) in the unaffected limb. Administer IV fluids (crystalloids, e.g., normal saline or Ringer's lactate) for hypotension.
  2. Vital Signs: Monitor continuously (HR, BP, RR, SpO2, temperature).
  3. Pain Control: Administer systemic analgesia (e.g., Paracetamol, NSAIDs cautiously in viper bites due to bleeding risk; opioids like morphine for severe pain).
  4. Tetanus Prophylaxis: Administer tetanus toxoid (Td/Tdap) or tetanus immunoglobulin (TIG) as per national guidelines based on vaccination status and wound characteristics.
  5. Wound Care: Clean the wound gently with soap and water or antiseptic solution. Do not apply pressure. Dress loosely.
  6. Baseline Assessments: Obtain initial laboratory tests (CBC, coagulation profile, renal function, CK) and perform 20WBCT.
• Emergency (Antivenom Administration):
  • Indications for Antivenom: Antivenom is the only specific antidote for snake envenomation. Indications depend on the type of snake and severity of envenomation.
    • Systemic Envenomation:
      • Evidence of coagulopathy (e.g., prolonged 20WBCT, elevated PT/aPTT, low fibrinogen, spontaneous bleeding).
      • Neurotoxicity (ptosis, ophthalmoplegia, dysphagia, respiratory weakness).
      • Cardiovascular instability (hypotension, shock).
      • Acute Kidney Injury.
      • Hemolysis or rhabdomyolysis.
    • Severe Local Envenomation:
      • Rapidly progressing swelling crossing major joint lines.
      • Extensive blistering or tissue necrosis.
      • Significant limb swelling with signs of compartment syndrome (rarely confirmed).
      • Swelling affecting the head/neck, potentially compromising the airway.
  • Antivenom Dosing:
    • General Principle: The initial dose of antivenom (AV) is based on the severity of envenomation, not the patient's body weight or age. Children receive the same initial dose as adults.
    • Type: Use the most appropriate antivenom available (monovalent for specific species if known, or polyvalent if the species is unknown but regional snakes are covered).
    • Administration:
      • Reconstitute lyophilized antivenom with sterile water according to manufacturer's instructions.
      • Dilute the reconstituted antivenom in 50-100 mL (for children, adjust volume to avoid fluid overload) of normal saline or 5% dextrose.
      • Administer intravenously slowly over 60-90 minutes (some protocols suggest 10-15 minutes for first 10 mL, then faster if no reaction).
      • Initial Dose (Typical for polyvalent AV for systemic envenomation): Varies by product, but often 5-10 vials (e.g., 50-100 mL) for adults and children. Always refer to manufacturer's guidelines and local protocols.
  • Anaphylaxis to Antivenom:
    • Antivenoms are foreign proteins (equine or ovine IgG) and can cause hypersensitivity reactions, ranging from mild urticaria to severe anaphylaxis.
    • Pre-medication: Routine pre-medication (e.g., antihistamines, corticosteroids) is controversial. WHO advises against routine use as it may mask early signs of anaphylaxis or delay treatment. Administer only if prior history of antivenom reaction or severe allergies.
    • Management of Anaphylaxis:
      1. STOP antivenom infusion immediately.
      2. Epinephrine (Adrenaline): Administer intramuscularly (IM) (e.g., 0.3-0.5 mg for adults; 0.01 mg/kg for children, max 0.3 mg). Repeat every 5-15 minutes as needed.
      3. Airway/Breathing: Maintain airway, administer oxygen, prepare for intubation if laryngeal edema or bronchospasm.
      4. Circulation: IV fluids for hypotension, vasopressors if refractory shock.
      5. Antihistamines: H1-blockers (e.g., diphenhydramine IV) and H2-blockers (e.g., ranitidine IV).
      6. Corticosteroids: IV corticosteroids (e.g., hydrocortisone IV) may be given, but are not first-line for acute anaphylaxis.
      7. Once stable, re-administer antivenom slowly with careful monitoring, potentially diluted further or pre-treated with antihistamines/corticosteroids.
  • Post-Antivenom Monitoring:
    • Observe closely for at least 1-2 hours for anaphylaxis.
    • Repeat 20WBCT, CBC, and coagulation profile 6 hours after initial antivenom dose (or 12-24 hours for neurotoxicity, depending on species).
    • Further Doses: If 20WBCT remains unclotted, or if systemic symptoms persist/reappear (recurrent coagulopathy, progressive neurotoxicity), administer further doses of antivenom.

Chronic Management

• Pharmacological:
  • Antibiotics: Prophylactic antibiotics are generally not recommended. Administer only if clear signs of secondary bacterial infection develop (e.g., cellulitis, abscess). Common pathogens are Gram-negative bacilli (e.g., Pseudomonas) and anaerobes.
  • Pain Management: Continue analgesia as needed.
  • Tetanus Prophylaxis: Ensure full course if not already received.
  • Dialysis: For severe acute kidney injury, if indicated.
• Non-pharmacological:
  • Wound Care: Meticulous wound care for local tissue damage, including debridement of necrotic tissue once stable and demarcation is clear. May require skin grafting.
  • Physiotherapy: Important for maintaining limb function and preventing contractures, especially after severe local envenomation or compartment syndrome.
  • Psychological Support: Many patients experience anxiety, PTSD, or depression due to the traumatic event and potential long-term disability.
• Monitoring (Long-term):
  • Regular follow-up for wound healing, signs of infection.
  • Assessment of limb function and range of motion.
  • Monitoring for delayed complications such as serum sickness (typically 5-14 days post-antivenom), persistent coagulopathy, chronic renal insufficiency, or neurological deficits.
  • Monitor for delayed neurotoxicity or recurrence of paralysis.

Treatment Algorithms

• First-Line (Immediate assessment and specific treatment):
  1. Assess ABCs & Stabilize: IV access, fluids, oxygen, pain control.
  2. History & Physical Exam: Identify signs of envenomation severity.
  3. Bedside 20WBCT: Critical for Viperidae.
  4. Blood Tests: CBC, coag profile, renal function, CK.
  5. Antivenom Indication: If systemic envenomation (neurotoxicity, coagulopathy, shock, AKI, rhabdomyolysis) OR severe local envenomation, administer appropriate initial dose of antivenom IV.
  6. Monitor for Anaphylaxis: Be prepared with Epinephrine.
  7. Post-Antivenom Assessment: Repeat 20WBCT and blood tests at 6 hours.
• Second-Line (Supportive and advanced interventions):
  • Repeat Antivenom Doses: If initial antivenom dose is insufficient (e.g., 20WBCT remains unclotted, neurotoxicity progresses).
  • Fasciotomy: Rarely indicated and controversial. Should only be considered after adequate antivenom and only if there is documented compartmental pressure >30 mmHg AND clinical signs of limb ischemia (pain on passive stretch, diminished pulses, paresthesia, pallor, pulselessness). Most "compartment syndromes" in snakebite are due to diffuse tissue edema that resolves with antivenom.
  • Blood Products: Transfuse packed red blood cells (PRBCs) for significant hemorrhage (Hgb <7g/dL or symptomatic anemia), fresh frozen plasma (FFP) for active bleeding with coagulopathy if antivenom has been given but is not yet effective (use FFP cautiously as it can provide substrate for ongoing venom action, but may be life-saving for active bleeding), platelets for severe thrombocytopenia with bleeding (<20,000/µL or active bleeding <50,000/µL).
  • Mechanical Ventilation: For severe respiratory paralysis due to neurotoxicity.
  • Dialysis: For acute kidney injury if indications for renal replacement therapy are met.
• Refractory Cases:
  • Persistent Coagulopathy: Continue repeat doses of antivenom until 20WBCT clots normally (or PT/aPTT normalize). Consider different batches or brands of antivenom if available.
  • Persistent Neurotoxicity: Continue supportive care and mechanical ventilation. Some neurotoxins are slowly reversible, and recovery can take days to weeks. Anticholinesterase inhibitors (e.g., neostigmine) may be temporarily effective for some postsynaptic neurotoxins (e.g., Naja spp.), but not presynaptic toxins. A test dose of neostigmine (e.g., 0.5-2.5 mg IV with atropine 0.6 mg IV) can be tried for Elapidae bites.
  • Severe Local Necrosis: Requires surgical debridement, skin grafting, and potentially amputation in extreme cases. Delay debridement until stable and demarcation is clear (days to weeks).

Complications

• Common:
  • Local tissue damage: Swelling, blistering, cellulitis, abscess formation, tissue necrosis.
  • Secondary bacterial infection of the bite wound.
  • Venom-induced consumption coagulopathy (VICC): Spontaneous bleeding.
  • Acute kidney injury (AKI).
  • Rhabdomyolysis.
  • Serum sickness: A delayed hypersensitivity reaction to antivenom (Type III), occurring 5-14 days after antivenom administration. Symptoms include fever, rash (urticarial, morbilliform), arthralgia, myalgia, lymphadenopathy. Managed with antihistamines and corticosteroids.
• Serious:
  • Intracranial hemorrhage: A devastating complication of severe coagulopathy.
  • Compartment syndrome: Rare but limb-threatening, leading to muscle and nerve damage, requiring fasciotomy.
  • Respiratory failure: Due to neurotoxic paralysis or severe pulmonary edema.
  • Anaphylaxis to antivenom.
  • Severe hypotension and shock.
  • Multi-organ dysfunction syndrome.
• Long-term:
  • Amputation or severe functional disability of the bitten limb.
  • Chronic pain, neuropathy.
  • Chronic kidney disease or end-stage renal disease.
  • Permanent neurological deficits (e.g., persistent ptosis, weakness).
  • Psychological sequelae: Post-traumatic stress disorder (PTSD), anxiety, depression.
  • Disfigurement and social stigma.

Prognosis

• Factors: Prognosis is influenced by:
  • Snake Species: Bites from highly venomous species (e.g., inland taipan, some mambas) carry a worse prognosis if not treated promptly.
  • Amount of Venom Injected: Larger venom doses result in more severe envenomation.
  • Bite Site: Bites to the head, neck, or torso are more dangerous than limb bites due to proximity to vital organs and larger vascular supply.
  • Time to Antivenom Administration: Earlier administration of adequate antivenom significantly improves outcomes and reduces complications.
  • Patient Characteristics: Children and the elderly are more vulnerable. Presence of comorbidities (e.g., chronic renal disease, heart disease) can worsen prognosis.
  • First Aid Measures: Inappropriate first aid (e.g., tourniquets, incision) can worsen outcomes.
  • Quality of Medical Care: Access to prompt, appropriate medical care, including intensive care, is crucial.
• Survival: While hundreds of thousands die annually, global case fatality rates vary widely, from <1% in regions with excellent antivenom access to >10-20% in areas with limited resources. Many deaths are preventable with timely treatment.
• Quality of Life: Even survivors often face significant long-term morbidity, including physical disability, chronic pain, and psychological distress, severely impacting their quality of life and economic productivity.

Prevention

• Primary (Preventing initial occurrence):
  • Education: Community education campaigns on snakebite prevention, recognition, and appropriate first aid.
  • Protective Clothing: Encourage wearing closed-toe shoes or boots and long trousers, especially when working in fields, walking in bushy areas, or at night.
  • Environmental Control: Clear bushes and tall grass around homes, keep premises tidy, block holes in walls, use mosquito nets tucking them under mattresses.
  • Behavioral Modification: Avoid walking in high-risk areas at night without a light source, do not sleep on the ground, avoid handling or approaching snakes, do not put hands into unseen places (e.g., under rocks, in crevices).
• Secondary (Early detection and intervention):
  • Rapid Transport: Prompt transfer of bite victims to a medical facility equipped to manage envenomation (i.e., with antivenom and resuscitation capabilities).
  • Community First Responders: Training community health workers in appropriate pre-hospital care and rapid referral.
  • Avoid Harmful First Aid: Dispel myths about ineffective and harmful traditional remedies or "first aid" measures (e.g., tourniquets, suction, incision).
• Tertiary (Preventing complications):
  • Timely and Adequate Antivenom: The most critical tertiary prevention measure to minimize venom effects and prevent severe complications.
  • Aggressive Supportive Care: Management of complications like AKI, respiratory failure, shock, and secondary infections.
  • Rehabilitation: Physiotherapy and occupational therapy to maximize functional recovery after limb damage or neurological deficits.
  • Psychological Support: Addressing the mental health impact of snakebite trauma.

Special Populations

• Pediatric:
  • Higher Venom-to-Body Mass Ratio: Children are more susceptible to severe systemic effects from a given venom dose due to their smaller body mass.
  • More Rapid Onset: Symptoms may develop and progress more quickly.
  • Fear and Anxiety: Children may be more distressed, making assessment difficult.
  • Antivenom Dosing: The initial dose of antivenom is the same for children as for adults because the dose required is based on the amount of circulating venom, not body weight.
  • Fluid Management: Careful monitoring of fluid balance to prevent overload.
• Geriatric:
  • Comorbidities: Elderly patients often have underlying medical conditions (e.g., cardiovascular disease, renal impairment) that can complicate management and increase susceptibility to venom effects or treatment side effects.
  • Medication Interactions: Potential for drug interactions.
  • Delayed Presentation: May present later due to reduced awareness or limited mobility.
  • Increased Risk of Complications: Higher risk of AKI, hemorrhage, and adverse drug reactions.
• Pregnancy:
  • Snake envenomation in pregnancy is a serious threat to both mother and fetus.
  • Antivenom is safe and indicated in pregnant women with envenomation. The benefits of antivenom outweigh potential risks to the fetus.
  • Close monitoring of maternal vital signs, fetal heart rate, and uterine activity.
  • Potential for premature labor, miscarriage, or stillbirth, especially with severe envenomation.
• Comorbidities:
  • Renal Disease: Patients with pre-existing renal impairment are at higher risk for severe AKI and may require earlier dialysis.
  • Cardiac Disease: More susceptible to venom-induced hypotension, arrhythmias, and fluid overload.
  • Bleeding Disorders: Coagulopathy from viper venom can be catastrophic in patients with pre-existing bleeding disorders or those on anticoagulants. Careful monitoring and aggressive reversal strategies may be needed.
  • Immunocompromised: Higher risk of secondary infections.

Clinical Pearls

• Diagnostic:
  • The 20WBCT is your best friend: It's a cheap, rapid, reliable bedside test for systemic coagulopathy from viper bites. Perform it on arrival and repeat every 6-12 hours until stable, even if initial clot is firm.
  • Clinical Syndrome is King: Do not wait for snake identification. Base management decisions on the evolving clinical picture (local effects, signs of neurotoxicity, coagulopathy).
  • Swelling Progression: Measure and mark limb swelling regularly. Rapid progression indicates significant envenomation.
  • Dry Bites: Up to 50% of venomous snake bites are dry bites. Observe for at least 8-12 hours. If no signs of envenomation develop, discharge.
• Treatment:
  • Antivenom is the ONLY specific antidote: Administer promptly if indicated. The initial dose is not weight-dependent for children vs. adults.
  • Anaphylaxis is manageable: Do not withhold antivenom for fear of anaphylaxis if indicated. Be prepared with epinephrine and resuscitation equipment.
  • No Tourniquets/Incisions: These are harmful and increase morbidity.
  • Fasciotomy is Rarely Indicated: Most "compartment syndromes" in snakebite are due to diffuse edema that resolves with antivenom. Surgical intervention should be a last resort and confirmed with compartment pressure measurements.
  • Respiratory Paralysis: In neurotoxic envenomation, patients can be fully alert but unable to breathe. Early intubation saves lives.
  • Delayed Effects: Be aware that neurotoxicity (especially from Kraits) or coagulopathy can be delayed by several hours. Maintain observation for an adequate period.
• Pitfalls:
  • Misidentification of snake: Leads to inappropriate or delayed treatment.
  • Over-reliance on traditional remedies: Delays definitive care.
  • Inadequate antivenom dosing: Leading to treatment failure and recurrent envenomation.
  • Pre-emptive fasciotomy: Unnecessary surgery with high complication rates.
  • Premature discharge: Missing delayed effects.
  • Ignoring a "dry bite" leading to a "systemic bite": A dry bite cannot be definitively confirmed immediately. Observation is key.

Recent Updates

• WHO Guidelines: The World Health Organization (WHO) has made snakebite envenoming a priority neglected tropical disease (NTD) and has published global strategies and guidelines for prevention and management, emphasizing improved access to safe, effective antivenoms.
• Antivenom Development: Efforts are ongoing to develop next-generation antivenoms that are broader spectrum, safer, more affordable, and more stable (e.g., heat-stable). Research into novel venom inhibitors is also active.
• Point-of-Care Diagnostics: Research into rapid, accurate point-of-care diagnostics for snake identification and venom detection is progressing, though not yet widely available for clinical use.
• Public Health Initiatives: Increased focus on public health interventions, community engagement, and strengthening healthcare systems in endemic areas.

Key References

• Guidelines:
  • WHO Guidelines for the Management of Snakebites: Comprehensive global guidelines covering epidemiology, clinical management, and public health aspects. Available on the WHO website.
  • Regional Protocols: Many countries/regions have specific guidelines based on local snake fauna (e.g., Australian Snakebite Management Guidelines, Indian National Snakebite Management Guidelines).
• Studies:
  • White, J. (2012). Snakebite envenoming: A global neglected health issue. Transactions of the Royal Society of Tropical Medicine and Hygiene, 106(6), 332-333.
  • Warrell, D. A. (2010). Guidelines for the management of snake-bites in sub-Saharan Africa. African Journal of Emergency Medicine, 1(1), 31-41. (An older but still foundational work).
  • Key clinical trials demonstrating efficacy of various antivenoms and treatment protocols in specific regions.
• Reviews:
  • Gutiérrez, J. M., et al. (2017). Snakebite envenoming: a disease of poverty. PLoS Neglected Tropical Diseases, 11(6), e0005602.
  • Longbottom, J., et al. (2018). Venomous snakebites in humans: an overview of clinical aspects and treatments. Toxicon, 151, 10-18.